Experienced in Infantile Neutropenia
Experienced in Infantile Neutropenia
100 Mario Capecchi Dr, 
Salt Lake City, UT 

Overview

Phillip Barnette is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Barnette is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Langerhans Cell Histiocytosis, Leukemia, Hepatoblastoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 70 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Infantile Neutropenia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in UT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

100 Mario Capecchi Dr, Salt Lake City, UT 84113

Additional Areas of Focus

Dr. Barnette has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


70 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
View 41 Less Clinical Trials
Similar Doctors
Advanced in Infantile Neutropenia
Pediatric Hematology Oncology
Advanced in Infantile Neutropenia
Pediatric Hematology Oncology

Primary Children's Hospital - Hematology Oncology

100 North Mario Capecchi Drive, Suite 1400, 
Salt Lake City, UT 
 (0.1 miles away)
Experience:
35+ years
Languages Spoken:
English, Japanese
Accepting New Patients

Dr. Pulsipher is currently the Division Chief of the Pediatric Hematology at Intermountain Primary Children's Hospital and Oncology, Director of the Children's and Adolescent Cancer Initiative at Huntsman Cancer Institute and a Presidential Chair in Pediatric Oncology and Hematology at the University of Utah. �Dr. Pulsipher is an internationally recognized expert in Bone Marrow Transplantation and Cellular Therapy, having directed the world's largest pediatric transplant research group for more than a decade (Pediatric Transplantation and Cellular Therapy Consortium). �He has run more than 20 multicenter trials in the field and is considered and expert in broad areas of transplantation and cellular therapy. �Areas of focus have included development of reduced toxicity approaches to transplantation of both malignant and non-malignant disorders with a focus on minimizing short and long-term effects of transplant. �For non-malignant disorders he has run national protocols that have improved safety for patients with immunodeficiencies, HLH, and bone marrow failure. For cancer, he has developed techniques allowing identification of patients who can avoid radiation-based treatments for leukemia. �This has included a novel approach to safer transplantation of patients using half-matched family donors (haploidentical donors) using a novel form of bone marrow graft engineering called alpha-beta T-cell depletion. �His desire to develop safer approaches has become a major focus as he has led major studies in the field of chimeric antigen receptor T-cells (CAR T-cells), a safer approach to cancer cure. �Dr. Pulsipher's work in cell therapy helped lead to the FDA approval of the first CART cell treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral Specific T-cell therapies. He has open protocols aimed at improving outcomes and his lab efforts are focused on making CAR T-cells that last longer and avoid overcome resistance by cancer cells. Dr. Pulsipher's interests have included ensuring that the families of those undergoing transplantation and cell therapy are psychologically well throughout the process. �To help with this, he has run several large trials assessing the safety and Quality of Life of pediatric bone marrow donors and is he currently running a large national trial looking at the psychological well-being of donor and recipient families as they go through the transplant process.For questions regarding Dr. Pulsipher's adult practice at the Huntsman Cancer Institute, or for questions about any of our clinical programs and for assistance identifying the right Hematology specialist for you or your family member, please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-4652. For questions regarding Dr. Pulsipher's pediatric practice and the Blood and Marrow Transplant Program at Primary Children's Medical Center, please call (801) 662-4830. Dr. Pulsipher is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Severe Combined Immunodeficiency (SCID), and Bone Marrow Transplant.

Advanced in Infantile Neutropenia
Pediatric Hematology Oncology
Advanced in Infantile Neutropenia
Pediatric Hematology Oncology

Primary Children's Hospital - Hematology Oncology

100 North Mario Capecchi Drive, Suite 1400, 
Salt Lake City, UT 
 (0.1 miles away)
Experience:
45+ years
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Richard Lemons, MD, PhD, is a professor in the Department of Pediatrics at the University of Utah School of Medicine, medical director and chief of pediatric hematology/oncology at Primary Children's Medical Center and the University of Utah, and a Huntsman Cancer Institute investigator. He is involved in various clinical trials for pediatric malignancies and pediatric hematologic disorders.Lemons earned a medical degree from George Washington University School of Medicine, Washington, DC; and performed an internship and residency at Johns Hopkins Hospital, Baltimore. Lemons was a staff member at St. Jude Children's Research Hospital prior to joining the University of Utah Department of Pediatrics. He is board certified in Pediatrics and Pediatric Hematology-Oncology. Dr. Lemons is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Hemophilia B, Infantile Neutropenia, Blood Clots, and Hemophilia A.

Advanced in Infantile Neutropenia
Pediatric Hematology Oncology
Advanced in Infantile Neutropenia
Pediatric Hematology Oncology
100 Mario Capecchi Dr, Ste 4100, 
Salt Lake City, UT 
 (0.1 miles away)
Languages Spoken:
English
Offers Telehealth

Anupam Verma is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Verma is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Infantile Neutropenia, and Febrile Neutropenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barnette's expertise for a condition
ConditionClose
      View All 18 Advanced Conditions
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile